Identifying the Axillary Substructure at Risk for Lymphedema in Operable Patients With Breast Cancer Receiving Regional Nodal Irradiation

Read full text
Authors: J Y Huang, Siyue Zheng, Maochen Zhang, S. Zhang, Jing-Jing Cao, Kun-Wei Shen, wei-xiang Qi, Gang Cai, L. Cao, Jiayi Chen
Cited by: 2
References: 41

Abstract

PURPOSE: Axillary substructures may contribute to the development of breast cancer-related lymphedema (BCRL). This study aimed to compare dose-volume parameters of various substructures to identify high-risk regions associated with BCRL and to evaluate the clinical applicability of these findings. METHODS AND MATERIALS: Cohort-Initial included 336 patients with pT1-3N0-1M0 breast cancer who underwent mastectomy or lumpectomy with axillary lymph node dissection (ALND) and regional nodal irradiation (RNI) between August 2018 and February 2021. The Norman questionnaire was used to assess BCRL. Thirteen dose-volume parameters across 8 axillary substructures were assessed for association with BCRL. Cohort-Recurrence comprised 50 consecutive ALND-treated patients with regional nodal recurrence diagnosed using positron emission tomography/computed tomography, used to evaluate the recurrence risk in the candidate substructures. Cohort-Reoptimization involved 20 patients from the Cohort-Initial who received excessive radiation doses in the candidate substructure. Their treatment plans were reoptimized to assess the feasibility of dose reduction while maintaining target coverage and organ dose. RESULTS: was feasible without compromising the radiation therapy plan quality. CONCLUSIONS: < 79.2% may serve as a recommended dose constraint for patients undergoing RNI after ALND. Avoiding excessive radiation to the ALTJ is clinically feasible and safe, potentially mitigating BCRL risk without compromising dose coverage to high-risk nodal regions.

Fields of Study & Subjects

Lymphatic System and Diseases Breast Cancer Treatment Studies Male Breast Health Studies

Publication details

Journal / source
Practical Radiation Oncology
Publisher
Elsevier BV
Volume
16
Issue
2
Pages
e90–e100
Publication date
13 January 2026
Language
EN